Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline

European Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2002, Pages 259-263

  Palovaara, Sanna ^a   Anttila, Markku ^a   Nyman, Leena ^a   Laine, Kari ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Drug interaction; Hormone replacement therapy (HRT); Selegiline

Indexed keywords

DRUG METABOLITE; ESTRADIOL VALERATE PLUS NORGESTREL; METHAMPHETAMINE; NORSELEGILINE; SELEGILINE; UNCLASSIFIED DRUG; AMPHETAMINE DERIVATIVE; DESMETHYLSELEGILINE; DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTRADIOL VALERATE; LEVONORGESTREL; MONOAMINE OXIDASE INHIBITOR; PROGESTERONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPARATIVE STUDY; DRUG INTERACTION; ESTROGEN THERAPY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINES; AREA UNDER CURVE; COMPARATIVE STUDY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, SYNTHETIC; FEMALE; HUMAN; LEVONORGESTREL; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITORS; PROGESTATIONAL HORMONES, SYNTHETIC; SELEGILINE; ESTRADIOL CONGENERS; HUMANS; PROGESTERONE CONGENERS;

EID: 0036020444     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0469-y     Document Type: Article

References (22)

1. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites
2. Pharmacokinetics of selegiline after oral dosing
3. Selegiline metabolism and cytochrome P450 enzymes: In vitro study in human liver microsomes
4. In vitro metabolism studies of selegiline using human liver microsomes: CYP enzyme identification and inhibition
5. Mechanism-based inactivation of cytochrome P450 2B6 by 17alpha-ethynylestradiole
6. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
7. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450
8. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel
9. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination
10. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
11. Dose linearity study of selegiline pharmacokinetics after oral administration: Evidence for strong drug interaction with female sex steroids
12. Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17α-ethinyloestradiol. Relative activities of rat and human liver enzymes
13. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation
14. The effect of hormone replacement therapy on CYP3A activity
15. CYP2D6 polymorphism is not crucial for the disposition of selegiline
16. Lack of effect of oral contraceptive use on the pharmacokinetics of quinine
17. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers
18. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6
19. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline
20. Contribution of CYP3A4 to selegiline metabolism in rat and human liver microsomes
21. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
22. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy